Prosecution Insights
Last updated: April 19, 2026

Examiner: GALSTER, SAMUEL LEONARD

Tech Center 1600 • Art Units: 1623 1693

This examiner grants 54% of resolved cases

Performance Statistics

54.0%
Allow Rate
-6.0% vs TC avg
155
Total Applications
+38.2%
Interview Lift
1178
Avg Prosecution Days
Based on 100 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
16.8%
§102 Novelty
37.9%
§103 Obviousness
25.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18558874 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO Non-Final OA EMORY UNIVERSITY
17620645 PURIFICATION METHODS FOR CARBOHYDRATE-LINKED OLIGONUCLEOTIDES Final Rejection AMGEN INC.
19275384 VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE Final Rejection Bio-Synthesis, Inc.
18259368 DISACCHARIDES FOR TREATING BONE DISEASES Non-Final OA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
17616966 METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH) Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18031832 CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE Non-Final OA The Regents of the University of Michigan
18539559 OIL-RESISTANT AGENT Non-Final OA DAIKIN INDUSTRIES, LTD.
18558808 COMPOSITION AND METHODS USING COMBINATION OF NARH AND NR TO PRODUCE INTRACELLULAR NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
18255757 STABLE AQUEOUS COMPOSITION FOR PRETERM TO PROMOTE EARLY POSTNAL GROWTH Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
17633254 HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B Final Rejection The Board of Trustees of the University of Illinois
17291588 METHODS FOR CONSOLIDATING ANTIBIOTIC-ELUTING POLYMERIC MATERIALS Non-Final OA THE GENERAL HOSPITAL CORPORATION
17258868 POLYMER COMPOUND AND PROMOTER FOR INTRODUCING COMPOUND INTO CELLS USING SAME Non-Final OA ADEKA CORPORATION
18269213 MOLECULE FOR INDUCING SPONTANEOUS CALCIFICATION OF TUMOR CELLS AND USE THEREOF Non-Final OA ZHEJIANG UNIVERSITY
18263124 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE Non-Final OA Daiichi Sankyo Company, Limited
18252838 COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE Final Rejection DAIICHI SANKYO COMPANY, LIMITED
17918725 THYCLOTIDES Final Rejection The United States of America,as represented by the Secretary,Department of Health and Human Services
18742011 HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR PURIFICATION OF OLIGONUCLEOTIDES Final Rejection Biogen MA Inc.
18655834 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents Non-Final OA Rubedo Life Sciences, Inc.
18121090 OPTIMIZED METHOD FOR DECONTAMINATING PRODUCTION OF GLUCOSE POLYMERS AND GLUCOSE POLYMER HYDROLYZATES Non-Final OA ROQUETTE FRERES
18693693 Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer Non-Final OA Whispergenics. Inc.
17610440 ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION Non-Final OA Scynexis, Inc.
17610900 NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES Final Rejection Nuclera Ltd
18035987 COMPOSITION, PHARMACEUTICAL COMPOSITION, USE OF A STABLE TOPICAL COMPOSITION COMPRISING A NANOEMULSION AND OF AT LEAST ONE ANTILEISHMANIAL COMPOUND, AND METHOD FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS Final Rejection Fundação Oswaldo Cruz
18569567 ONE-POT PRODUCTION OF CELLULOSE NANOCRYSTALS Non-Final OA NANO-GREEN BIOREFINERIES INC.
18564331 NOVEL PHENYLPROPANOID COMPOUND Non-Final OA NABOCUL COSMETICS CO., LTD.
18000962 RNA PURIFICATION METHOD Non-Final OA ETHERNA IMMUNOTHERAPIES NV
18288057 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND Non-Final OA NIPPON SHINYAKU CO., LTD.
17542693 FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF Non-Final OA SICHUAN FUSHENGYUAN TECHNOLOGY CO., LTD
18266331 PHARMACEUTICAL APPLICATION OF FUSED RING PHENOLIC COMPOUNDS Non-Final OA RISEN (SUZHOU) PHARMA TECH CO. LTD.
18281352 N-(2-AMINOETHYL)MORPHOLINE-BASED RNA ANALOGS, METHOD FOR THE PREPARATION AND USE THEREOF Non-Final OA Uniwersytet Warszawski

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month